TWST - Twist Bioscience Corporation
After hours:
| Previous close | 16.19 |
| Open | 16.06 |
| Bid | 16.21 x 4000 |
| Ask | 17.12 x 900 |
| Day's range | 15.86 - 17.11 |
| 52-week range | 11.46 - 58.76 |
| Volume | |
| Avg. volume | 1,415,847 |
| Market cap | 970.358M |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.97 |
| Earnings date | 03 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.88 |
Simply Wall St.We're Hopeful That Twist Bioscience (NASDAQ:TWST) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Business WireTwist Bioscience and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research
SOUTH SAN FRANCISCO, Calif., May 31, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and CeGaT GmbH, a global provider of sequencing services for research, clinical studies, and human genetic diagnostics, today announced the launch of the Twist Alliance CeGaT RNA Fusion Panel, which is designed to detect RNA fusions and conduct transcript variant analysis for oncology researc
Business WireTwist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 24, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:
Business WireTwist Bioscience Appoints Robert Werner as Chief Accounting Officer
SOUTH SAN FRANCISCO, Calif., May 23, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer.
Business WireTwist Bioscience Launches Portfolio of RNA Sequencing Tools
SOUTH SAN FRANCISCO, Calif., May 22, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a portfolio of RNA sequencing tools, which includes the Twist RNA Exome, Twist RNA Library Prep Kit and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing
Business WireTwist Bioscience to Present at ITF World 2023
SOUTH SAN FRANCISCO, Calif., May 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at Imec Technology Forum (ITF) World 2023 in Antwerp, Belgium on Wednesday, May 17th at 11:10 AM CEST.
- Simply Wall St.
Investors Don't See Light At End Of Twist Bioscience Corporation's (NASDAQ:TWST) Tunnel
With a price-to-sales (or "P/S") ratio of 3.2x Twist Bioscience Corporation ( NASDAQ:TWST ) may be sending very bullish...
ZacksTwist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireTwist Bioscience Reports Fiscal Second Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., May 05, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2023 ended March 31, 2023.
ZacksHorizon Therapeutics (HZNP) Q1 Earnings and Revenues Lag Estimates
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -29.06% and 7.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Motley Fool3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
If there's one word you could use to describe the kinds of stocks that Cathie Wood buys, it would be "innovative." In fact, three of her ARK Invest exchange-traded funds (ETFs) include the word "innovation" in their names. Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (NASDAQ: BEAM).
ZacksTwist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireTwist Bioscience and Aster Insights Partner on Launch of Next Generation Oncology Panel for Cancer Research
SOUTH SAN FRANCISCO, Calif. & TAMPA, Fla., April 27, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Aster Insights, a bioinformatics company with the most advanced, direct-patient, lifetime-consented clinicogenomics data to accelerate oncology discovery research, today announced the availability of the AsterExome panel, which can simultaneously enable whole exome sequenc
Motley FoolCathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought
The iconic money manager with a penchant for aggressive growth is staying active as her exchange-traded funds bounce back in 2023.
Business WireTwist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies
SOUTH SAN FRANCISCO, Calif., April 20, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura., "Astellas"), by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development.
Business WireTwist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies
SOUTH SAN FRANCISCO, Calif., April 13, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist T-cell Receptor (TCR), and Twist chimeric antigen receptor (CAR) Libraries. These new libraries provide researchers with the ability to rapidly create custom libraries that can enable the identification and development of next generation cell therapies.
Business WireTwist Bioscience to Report Fiscal 2023 Second Quarter Financial Results on Friday, May 5, 2023
SOUTH SAN FRANCISCO, April 13, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, before the opening of the market on Friday, May 5, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discu
Business WireDNA Data Storage Alliance Announces Board Appointments
SAN DIEGO, March 29, 2023--The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance. David Turek will represent CATALOG and Don
- Simply Wall St.
Shareholders in Twist Bioscience (NASDAQ:TWST) are in the red if they invested a year ago
Investing in stocks comes with the risk that the share price will fall. And unfortunately for Twist Bioscience...
Business WireTwist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches
SOUTH SAN FRANCISCO, Calif., March 09, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an integrated offering of antibody discovery services available to customers. The offering combines Twist Biopharma’s synthetic libraries and AI machine learning with an in vivo immunization approach gained through the acquisition of Abveris, also known as Twist Boston. This
ZacksTwist Bioscience (TWST) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Twist Bioscience (TWST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Business WireTwist Bioscience Publishes Data on VHH Single Domain Antibody Discovery Using New Methodology on Optofluidic Platform
SOUTH SAN FRANCISCO, Calif., February 14, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today published on the successful discovery of alpaca-derived VHH antibodies using a disruptive, function-forward in vivo discovery workflow developed by Abveris, also known as Twist Boston, on the Beacon optofluidic platform. The paper, titled "Alpaca Single B Cell Interrogation and Hea
- Zacks
Twist Bioscience (TWST) Upgraded to Buy: Here's Why
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
Wall Street Analysts Predict a 26.05% Upside in Twist Bioscience (TWST): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Twist Bioscience (TWST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Business Wire
Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution at AGBT
SOUTH SAN FRANCISCO, Calif., February 07, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist enhanced Whole Genome Sequencing (eWGS) solution focused on non-human genomics applications, at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting in Hollywood, Florida. eWGS is a novel solution that enables rese